Transdermal compositions for anticholinergic agents
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-031/216
A61K-047/00
출원번호
US-0566900
(2012-08-03)
등록번호
US-8652491
(2014-02-18)
우선권정보
WO-PCT/EP00/07533 (2000-08-03)
발명자
/ 주소
Carrara, Dario Norberto R.
Grenier, Arnaud
출원인 / 주소
Antares Pharma IPL AG
대리인 / 주소
Winston & Strawn LLP
인용정보
피인용 횟수 :
0인용 특허 :
137
초록▼
The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation whi
The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.
대표청구항▼
1. A transdermal or transmucosal composition comprising: oxybutynin as an anti-cholinergic agent in an amount between 1 to 2% by weight of the composition; anda delivery vehicle comprising a C2 to C4 alkanol or a mixture thereof present in an amount of 45 to 63%, a polyalcohol present in an amount o
1. A transdermal or transmucosal composition comprising: oxybutynin as an anti-cholinergic agent in an amount between 1 to 2% by weight of the composition; anda delivery vehicle comprising a C2 to C4 alkanol or a mixture thereof present in an amount of 45 to 63%, a polyalcohol present in an amount of 1 to 5% selected from the group consisting of propylene glycol, dipropylene glycol, polyethylene glycol, glycerin, and mixtures thereof, a monoalkyl ether of diethylene glycol or a mixture thereof present in an amount of 2 to 10%, and water present in an amount of about 10 to about 25%;wherein all percentages are calculated by weight of the composition, and the weight ratio of the polyalcohol to the monoalkyl ether of diethylene glycol is between 1:2 and 1:10 to deliver the anticholinergic agent to a subject who receives the composition on a skin surface; andwherein the composition is substantially free of additional permeation enhancers to avoid deeper penetration of the anti-cholinergic agent and undesirable odor and irritation effects caused by permeation enhancers of conventional fatty compounds during use of the composition. 2. The composition of claim 1, wherein the oxybutynin is present as oxybutynin free base, as a pharmaceutically acceptable salt of oxybutynin, or as a mixture thereof, wherein the pharmaceutically acceptable salt of oxybutynin is selected from the group consisting of acetate, bitartrate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hydrobromide, hydrochloride, lactate, malate, maleate, mandelate, mesylate, methylnitrate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate, salicylate, stearate, succinate, sulfate, tannate and tartrate. 3. The composition of claim 1, wherein the alkanol is selected from the group consisting of ethanol, isopropanol, n-propanol, and mixtures thereof; wherein the polyalcohol is selected from the group consisting of propylene glycol, dipropylene glycol, and mixtures thereof; and wherein the monoalkyl ether of diethylene glycol is selected from the group consisting of monomethyl ether of diethylene glycol, monoethyl ether of diethylene glycol, and mixtures thereof. 4. The composition of claim 1 further comprising at least one excipient selected from the group consisting of gelling agents, antimicrobials, preservatives, antioxidants, buffers, humectants, sequestering agents, moisturizers, emollients, and film-forming agents, wherein the at least one excipient is not a permeation enhancer. 5. The composition of claim 1 in the form of a topical gel, lotion, foam, cream, spray, aerosol, ointment, emulsion, microemulsion, nanoemulsion, suspension, liposomal system, lacquer, patch, bandage, or occlusive dressing. 6. The composition of claim 1, wherein oxybutynin is in combination with a secondary active agent for concurrent administration. 7. The composition of claim 1, further comprising one or more moisturizers or emollients to soften and smoothen the skin or to hold and retain moisture thereon, wherein the one or more moisturizers or emollients is not a permeation enhancer. 8. The composition of claim 7, wherein the moisturizer or emollient is selected from the group consisting of cholesterol, light mineral oil, and petrolatum. 9. A method for administering an anti-cholinergic agent to an individual in need thereof which comprises topically administering a therapeutically effective amount of the composition of claim 1 to the individual upon a skin surface thereof. 10. The method of claim 9, which further comprises administering the composition from a metered-dose dispenser to apply between 1 and 5 grams of the composition upon a skin surface of 100 to 1500 cm2. 11. A transdermal or transmucosal composition consisting essentially of: oxybutynin as an anti-cholinergic agent in an amount between 1 to 2% by weight of the composition;a delivery vehicle consisting essentially of a C2 to C4 alkanol or a mixture thereof present in an amount of 45 to 63%, a polyalcohol present in an amount of 1 to 5% selected from the group consisting of propylene glycol, dipropylene glycol, polyethylene glycol, glycerin, and mixtures thereof, a monoalkyl ether of diethylene glycol or a mixture thereof present in an amount of 2 to 10%, and water present in an amount of about 10 to about 25; andat least one excipient selected from the group consisting of gelling agents, antimicrobials, preservatives, antioxidants, buffers, humectants, sequestering agents, moisturizers, emollients, and film-forming agents;wherein all percentages are calculated by weight of the composition, and the weight ratio of the polyalcohol to the monoalkyl ether of diethylene glycol is between 1:2 and 1:10 to deliver the anticholinergic agent to a subject who receives the composition on a skin surface; andwherein the composition is substantially free of additional permeation enhancers to avoid deeper penetration of the anti-cholinergic agent and undesirable odor and irritation effects caused by permeation enhancers of conventional fatty compounds during use of the composition. 12. A method for administering an anti-cholinergic agent to an individual in need thereof which comprises topically administering a therapeutically effective amount of the composition of claim 11 to the individual upon a skin surface thereof. 13. The method of claim 12, which further comprises administering the composition from a metered-dose dispenser to apply between 1 and 5 grams of the composition upon a skin surface of 100 to 1500 cm2. 14. A transdermal or transmucosal gel consisting of: oxybutynin as an anti-cholinergic agent in an amount between 1 to 2% by weight of the composition;a delivery vehicle consisting of a C2 to C4 alkanol or a mixture thereof present in an amount of 45 to 63%, a polyalcohol present in an amount of 1 to 5% selected from the group consisting of propylene glycol, dipropylene glycol, polyethylene glycol, glycerin, and mixtures thereof, a monoalkyl ether of diethylene glycol or a mixture thereof present in an amount of 2 to 10%, and water present in an amount of about 10 to about 25;a gelling agent; andat least one excipient selected from the group consisting of antimicrobials, preservatives, antioxidants, buffers, humectants, sequestering agents, moisturizers, emollients, and film-forming agents;wherein all percentages are calculated by weight of the composition, and the weight ratio of the polyalcohol to the monoalkyl ether of diethylene glycol is between 1:2 and 1:10 to deliver the anticholinergic agent to a subject who receives the composition on a skin surface; andwherein the gel is substantially free of additional permeation enhancers to avoid deeper penetration of the anti-cholinergic agent and undesirable odor and irritation effects caused by permeation enhancers of conventional fatty compounds during use of the gel. 15. A method for administering an anti-cholinergic agent to an individual in need thereof which comprises topically administering a therapeutically effective amount of the gel of claim 14 to the individual upon a skin surface thereof. 16. The method of claim 15, which further comprises administering the gel from a metered-dose dispenser to apply between 1 and 5 grams of the gel upon a skin surface of 100 to 1500 cm2.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (137)
Piasco Alain,FRX ; Lafay Jean,FRX ; Delansorne Remi,FRX ; Paris Jacques,FRX ; Pascal Jean-Claude,FRX, 19-nor-pregnene derivatives and pharmaceuticals containing such derivatives.
David Scott Dunlop ; Susan Marie Guskey ; Vicente Eduardo Leyba VE; Douglas Allan Royce, Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers.
Hartell, Mark G.; Bhattacharjee, Apurba K.; Hicks, Rickey P.; VanHamont, John E.; Milhous, Wilbur K., Artemisinins with improved stability and bioavailability for therapeutic drug development and application.
Carrara,Dario; Porto,Gabriel; Rodriguez,Jorge, Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels.
Kanios David P. ; Gentile Joseph A. ; Mantelle Juan A. ; Sablotsky Steven, Compositions and methods for topical administration of pharmaceutically active agents.
Kenneth B Kirby ; Berno I. R. Pettersson, Jr., Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof.
Oettel Michael,DEX ; Golbs Siegfried,DEX ; Dittgen Michael,DEX ; Timpe Carsten,DEX ; Graser Thomas,DEX ; Hubler Doris,DEX, Compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases.
Stella Valentino J. (Lawrence KS) Rajewski Roger (Lawrence KS), Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof.
Reed Barry Leonard,AUX ; Morgan Timothy Matthias,AUX ; Finnin Barrie Charles,AUX, Dermal penetration enhancers and drug delivery systems involving same.
Iles Martin C. (7 Cartwright Drive Shaw ; Swindon ; Wiltshire GBX) Atherton Angela D. (170 ; Windsor Drive Chelsfield ; Orpington ; Kent GBX) Copping Neil M. (8 Lautrec Way Haydon Hill ; Aylesbury ; , Freeze-dried dosage forms and methods for preparing the same.
Al-Razzak Laman A. ; Constantinides Panayiotis Pericleous ; Kaul Dilip ; Lipari John M. ; McChesney-Harris Lisa L. ; Abdullah Bashar Y., Hydrophilic binary systems for the administration of lipophilic compounds.
Wong Ooi (Fremont CA) Farinas Kathleen C. (San Francisco CA) Cleary Gary W. (Menlo Park CA) Chiang Chia-Ming (Foster City CA) Xia Jun (Redwood City CA), Method and device for providing nicotine replacement therapy transdermally/transbuccally.
Campbell Patricia S. (Palo Alto CA) Enscore David J. (Sunnyvale CA) Gale Robert M. (Los Altos CA) Kaufman Arnold (Palo Alto CA), Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix.
Osborne James L. (2365 Thompson Ct. Mountain View CA 94043) Nelson Melinda K. (1127 Hollenbeck Sunnyvale CA 94087) Enscore David J. (18291 Montpere Way Saratoga CA 95070) Yum Su I. (1021 Runnymead Ct, Method of administering nicotine transdermally.
Young James W. ; Brandt Steven, Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+).
Aberg Gunnar (Westborough MA) McCullough John R. (Worcester MA), Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin.
Berner Bret (Scarsdale NY) Ebert Charles (Salt Lake City UT) Mazzenga Gerard C. (New City NY) Otte John H. (Monsey NY), Mixed solvent mutually enhanced transdermal therapeutic system.
Kasting Gerald B. (Wyoming OH) Massaro Ellen R. (Cincinnati OH) Smith Ronald L. (West Chester OH) Snyder William E. (Cincinnati OH), Penetrating topical pharmaceutical compositions.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Rhodes John,GBX ; Rhodes Peter,GBX ; Evans Brian Kenneth,GBX, Pharmaceutical products containing a complex of an amide-type local anesthetic and a polyacrylate.
Punto Louis L. (Northport NY) Zecchino Jules R. (Closter NJ) Lentini Peter J. (Glen Oaks NY), Self-tanning cosmetic compositions and methods of using the same.
Chiang Chia-Ming (Foster City CA) Cleary Gary W. (San Mateo CA), Skin permeation enhancer compositions, and methods and transdermal systems associated therewith.
Chiang Chia-Ming (Foster City CA) Cleary Gary W. (San Mateo CA), Skin permeation enhancer compositions, and methods and transdermal systems associated therewith.
Stttgen Gnter (Berlin DEX) Schaefer Hans (Berlin DEX), Topical combinations of an a
상세보기
Sato ; deceased Toshiya (late of Kanagawa JPX by Kuniko Sato ; legal representative) Ishida Kenya (Kanagawa JPX), Topical composition for treating acne vulgaris.
Lipp Ralph,DEX ; Gunther Clemens,DEX ; Riedl Jutta,DEX ; Tauber Ulrich,DEX, Transdermal therapeutic systems that contain sex steroids and dimethyl isosorbide.
Quan Danyi (Salt Lake City UT) Deshpanday Ninad A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT) Ebert Charles D. (Salt Lake City UT), Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
Quan Danyi ; Deshpanday Ninad A. ; Venkateshwaran Srinivasan ; Ebert Charles D., Triacetin as a penetration enhancer for transdermal delivery of a basic drug.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.